Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

Cancer

Volumn 118, Issue 1, 2012, Pages 118-126

  Nicolini, Franck E ^a   Turkina, Anna ^b   Shen, Zhi Xiang ^c   Gallagher, Neil ^d   Jootar, Saengsuree ^e   Powell, Bayard L ^f   De Souza, Carmino ^g   Zheng, Ming ^d   Szczudlo, Tomasz ^d   Le Coutre, Philipp ^h  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d NOVARTIS PHARMA AG   (Switzerland)

^e MAHIDOL UNIVERSITY   (Thailand)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CAMPINAS   (Brazil)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

BCR ABL; chronic myeloid leukemia; chronic phase; ENACT; nilotinib

Indexed keywords

IMATINIB; NILOTINIB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATOBILIARY DISEASE; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMPASSIONATE USE TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 83855164150     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26249     Document Type: Article

References (10)

1. Goldman JM, Melo JV,. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1084-1086. (Pubitemid 32267980)
2. Kavalerchik E, Goff D, Jamieson CH,. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008; 26: 2911-2915.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004. (Pubitemid 36302244)
4. Manley PW, Stiefl N, Cowan-Jacob SW, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010; 18: 6977-6986.
5. O'Hare T, Walters DK, Deininger MW, Druker BJ,. AMN107: tightening the grip of imatinib. Cancer Cell. 2005; 7: 117-119. (Pubitemid 40248337)
6. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD,. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006; 94: 1765-1769. (Pubitemid 43882564)
7. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546. (Pubitemid 350159618)
8. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111: 1834-1839. (Pubitemid 351451490)
9. Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood. 2009; 114: 464. Abstract 1129.
10. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-2551. (Pubitemid 43882350)